Wenlong Wang

Prof. Dr. Wenlong Wang

School of Pharmaceutical Sciences, Jiangnan University, Wuxi 214122, China
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2022 in Chemical Biology & Drug Design
Verified
Journal Article
Closed access
SRSatheeshkumar Rajendran
Satheeshkumar Rajendran
KSKalaiselvi Sivalingam
Kalaiselvi Sivalingam
RJRajendra Prasad Karnam Jayarampillai
Rajendra Prasad Karnam Jayarampillai
WWWenlong Wang
Wenlong Wang
Cristian O. SalasCristian O. Salas
Cristian O. Salas

24 November 2023 in Journal of Materials Chemistry C
Verified
Journal Article
Closed access
PDF file
CZChun Zhang
Chun Zhang
YSYi-Tao Sun
Yi-Tao Sun
SGSuya Gan
Suya Gan
ARAimin Ren
Aimin Ren
SMSlieman Milaneh
Slieman Milaneh
WWWenlong Wang
Wenlong Wang
The work reports the progress of small-fluorescent molecules for bioimaging applications to cancer-relevant biomarkers H+, NO, H2S and reactive oxygen species (H2O2, HClO, O2˙−, 1O2 and ˙OH) over the past six years.

1 December 2017 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
WWWenlong Wang
Wenlong Wang
XCXiao-Yu Chen
Xiao-Yu Chen
YGYa Gao
Ya Gao
LGLi-Xin Gao
Li-Xin Gao
LSLi Sheng
Li Sheng
YZYubo Zhou
Yubo Zhou

31 July 2013 in Molecules
Verified
Journal Article
Open access
PDF file
WWWenlong Wang
Wenlong Wang
LSLijun Song
Lijun Song
XCXia Chen
Xia Chen
XYXu-Ren Yin
Xu-Ren Yin
WFWen-Hua Fan
Wen-Hua Fan
BFBainian Feng
Bainian Feng
The synthesis and structure-activity relationship (SAR) studies of praziquantel derivatives with activity against adult Schistosoma japonicum are described. Several of them showed better worm killing activity than praziquantel and could serve as leads for further optimization.

10 August 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
WWWenlong Wang
Wenlong Wang
CSCong Shen
Cong Shen
ZYZhi Yang
Zhi Yang
Objective: Distant metastasis (DM) is an important prognostic factor in differentiated thyroid cancer (DTC) and determines the course of treatment. This study aimed to establish a predictive nomogram model that could individually estimate the risk of DM and analyze the prognosis of female DTC patients (FDTCs).Materials and methods: A total of 26,998 FDTCs were retrospectively searched from the Surveillance, Epidemiology, and End Results (SEER) database from 2010 to 2018 and randomly divided into validation and training cohorts. Univariate and multivariate analyses were performed to screen for prognostic factors and construct a prediction nomogram. The performance of the nomogram was assessed by the area under the receiver operating characteristic curve (AUC), concordance index (C-index), and a calibration curve. The overall survival (OS) and cancer-specific survival (CSS) were evaluated by Kaplan–Meier (K-M) analysis.Results: A total of 263 (0.97%) FDTCs were reported to have DM. K-M analysis showed the association of multiple-organ metastases and brain involvement with lower survival rates (P < 0.001) in patients. Tumor size, age at diagnosis, thyroidectomy, N1 stage, T3–4 stage, and pathological type were independent predictive factors of DM in FDTCs (all P < 0.001). Similarly, age at diagnosis, Black, DM, T3–4 stage, thyroidectomy, and lung metastasis were determined as independent prognostic factors for FDTCs (all P < 0.001). Several predictive nomograms were established based on the above factors. The C-index, AUC, and calibration curves demonstrated a good performance of these nomogram models.Conclusion: Our study was successful in establishing and validating nomograms that could predict DM, as well as CSS and OS in individual patients with FDTC based on a large study cohort. These nomograms could enable surgeons to perform individualized survival evaluation and risk stratification for FDTCs.

28 February 2024 in Chemical Science
Verified
Journal Article
Open access
PDF file
YSYunkai Shi
Yunkai Shi
MLMinmin Liu
Minmin Liu
MLMengna Li
Mengna Li
YMYiwen Mao
Yiwen Mao
JMJingkun Ma
Jingkun Ma
BZBing Zhou
Bing Zhou
Peptidyl-prolyl cis/trans isomerase NIMA-interacting 1 (Pin1) is overexpressed and/or overactivated in many human cancers and has been shown to play a critical role during oncogenesis. Despite the potential of Pin1 as a drug target, its successful targeting has proved to be challenging. We speculate that only blocking the enzymatic function of Pin1 with inhibitors may not be sufficient to lead to a total loss-of-function. Here, we report the discovery of P1D-34, a first-in-class and potent PROTAC degrader of Pin1, which induced Pin1 degradation with a DC50 value of 177 nM and exhibited potent degradation-dependent anti-proliferative activities in a panel of acute myeloid leukemia (AML) cell lines. In contrast, Pin1 inhibitor Sulfopin did not show activity. More significantly, P1D-34 could sensitize Bcl-2 inhibitor ABT-199 in Bcl-2 inhibitor-resistant AML cells, highlighting the potential therapeutic value of targeted Pin1 degradation for Bcl-2 inhibitor-resistant AML treatment. Further mechanism study revealed that P1D-34 led to the up-regulation of ROS pathway and down-regulation of UPR pathway to induce cell DNA damage and apoptosis. Notably, we further demonstrated that treatment with the combination formula of glucose metabolism inhibitor 2-DG and P1D-34 led to a notable synergistic anti-proliferative effect, further expanding its applicability. These data clearly reveal the practicality and importance of PROTAC as a preliminary tool compound suitable for assessment of Pin1-dependent pharmacology and a promising strategy for AML treatment.